Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers

Sun, Feng; Han, Bangmin; Cui, Di; Zhao, Fu-Jun; Sun, Xiaojiang; Zhuo, Jian; Jing, Yifeng; Liu, Haitao; Xia, Shujie; Yang, Yong; Luo, Guangheng; Guo, Fengfu

doi:10.1007/s00345-014-1456-5

Cited by 41 publications

(30 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These rates are well comparable to the HoLEP (0–44%) [2, 3, 27], TURP (0–38%) [2, 3, 27], ThuVEP (5.6–27%) [8, 17, 24], PVP (0–22%) [27] and ThuVaRP (8.5–23.1%) [9, 12, 23, 25] series. However, the actual rates of transient incontinence after TURP and laser prostatectomy are presumably higher due to a lack of a standardized reporting postoperative transient incontinence and dysuria.…”

Section: Discussionsupporting

confidence: 49%

“…The perioperative Hb decrease was significantly higher after ThuVEP compared to that after ThuVaRP (0.9 vs. 0.4 g/dL), but the Hb decrease after ThuVEP in our series is well comparable to the Hb decrease in the ThuVaRP (0.8–0.92 g/dL) group [9, 12, 23, 26] and ThuVEP literature [16-18]. In accordance with the low Hb decrease, the rate of postoperative blood transfusions was low and not different between both groups (1.3%) and in line with the HoLEP [2, 3], PVP [2, 3], ThuVaRP [4, 6, 9-14, 22-26], and ThuVEP [7, 8, 16-18] literature.…”

Section: Discussionmentioning

confidence: 70%

“…Each of these complications is in line with the HoLEP [2, 3, 27], TURP [2, 3, 27] and ThuVEP [7, 17, 24, 30] literature. To note, Sun et al [12] described an immediate RR of 2.2% in the largest ThuVaRP series of 2,216 patients so far. In addition, Chun et al[24] reported an immediate RR of 5.3% after ThuVEP and ThuVaRP each respectively.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

et al. 2017

View full text Add to dashboard Cite

Introduction: To evaluate the intermediate-term outcomes of thulium vapoenucleation of the prostate (ThuVEP) and thulium vaporesection of the prostate (ThuVaRP) in patients with benign prostate obstruction (BPO). Materials and Methods: A bicentric retrospective matched-paired comparison of patients treated by ThuVEP (n = 80) or ThuVaRP (n = 80) was performed. The patients were preoperatively assessed with International Prostate Symptom Score (IPSS), quality of life (QoL), post-void residual urine (PVR), maximum urinary flow rate (Qmax), prostatespecific antigen (PSA) and re-evaluated at 12- and 24-month follow-up. Results: Median prostate volume was 65 mL and not different between the groups. The immediate re-operation rate was significantly different between ThuVEP and ThuVaRP (5 vs. 0%, p ≤ 0.0434). IPSS, QoL, Qmax and PVR had improved significantly compared to preoperative assessment in both groups at 12- and 24-month follow-up (p ≤ 0.001). Median Qmax (18.2 vs. 21.0 mL/s) and PVR (29.4 vs. 0 mL) were significantly different between ThuVEP and ThuVaRP at 24-month follow-up (p ≤ 0.001), while IPSS and QoL showed no differences between the groups. However, the PSA reduction was significantly higher after ThuVEP compared to ThuVaRP (78.93 vs. 23.39%, p ≤ 0.006) at 24-month follow-up. Conclusions: ThuVEP and ThuVaRP are safe and efficacious procedures for patients with BPO. Although the peri-operative re-intervention rates were lower after ThuVaRP, the low PSA reduction rate after ThuVaRP at 24-month follow-up favours the ThuVEP procedure.

show abstract

Section: Discussionsupporting

confidence: 49%

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In 2014, Sun and colleagues evaluated the longterm durability and complication rates after TmLRP through a large, prospective, multicenter study [Sun et al 2015]. A total of 2016 patients were treated with TmLRP at four medical centers and were followed for up to 8 years (61.1% followed for 5 years, 24.4% followed for 8 years One unique aspect of this study was the reporting of long-term complications.…”

Section: Thulium Laser Resection Of Prostate (Tmlrp)mentioning

confidence: 99%

Evidence of the efficacy and safety of the thulium laser in the treatment of men with benign prostatic obstruction

Barbalat

Velez

Sayegh

et al. 2016

Therapeutic Advances in Urology

View full text Add to dashboard Cite

In 2005, the high power thulium laser was introduced for the surgical treatment of benign prostatic obstruction. It has several properties that confer theoretical advantages over other lasers used for the same indication, such as technical versatility and a relatively small zone of thermal damage. Studies using the 70-150 W thulium laser systems demonstrate good efficacy of these procedures with low morbidity and few complications even in higher risk patients. Different techniques have been employed to treat the prostate with this technology, including enucleation, vapoenucleation, vaporization and resection. Comparative studies have been published comparing thulium laser prostatectomy to monopolar transurethral resection of prostate (TURP), bipolar TURP and holmium laser enucleation of prostate (HoLEP). In this review we discuss the current literature on the safety and efficacy of various thulium techniques for the treatment of benign prostatic hyperplasia and examine comparative studies.

show abstract

“…In 2010, an international group of users (Thulium Laser Working Group) evaluated and reflected in a consensus statement the development and early clinical results of this laser type [12], building on the first publication of 70-Watt Tm:YAG use in the prostate from 2007 [13]. Now, Xia and his co-workers, who reported their follow-up data on the Thulium laser operation in 2014 [14,15], contributed the first metaanalysis of nine RCTs on Tm:YAG vaporesection of the prostate (ThuVARP) [16].…”

mentioning

confidence: 99%

Update on lasers in urology 2015

Herrmann

Bach

2015

World J Urol

View full text Add to dashboard Cite

Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers

Abstract: Thulium laser resection of the prostate is a safe and effective procedure with excellent durability in the treatment of symptomatic BPH.

Cited by 41 publications

References 26 publications

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

Evidence of the efficacy and safety of the thulium laser in the treatment of men with benign prostatic obstruction

Update on lasers in urology 2015

Contact Info

Product

Resources

About